Product Highlight - LEQEMBI

The First ever disease-modifying therapy for early Alzheimer’s Disease

• LEQEMBI^® is indicated for the treatment in adult patients with MCI due to AD or Mild AD

• Dual-acting LEQEMBI^® clears not only plaques, but also protofibrils, the most neurotoxic form of amyloid-beta

• LEQEMBI^® demonstrated statistically significant slowing of cognitive and functional decline across primary and all secondary endpoints with continued treatment

MCI = mild cognitive impairment; AD = Alzheimer’s disease

References: 1. U.S. Food & Drug Administration. Available online. hps://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval. Last accessed: 28 June 2024. 2. LEQEMBI^® Hong Kong Prescribing Information (April 2024). 3. van Dyck CH, et al. New Engl J Med. 2023;388(1):9–21. 4. Hampel H, et al. Mol Psychiatry. 2021;26(10):5481–503.